Milestone Pharmaceuticals Inc. MIST
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -61.76%
- 1 year
- -58.02%
- Market cap
- 96.17M
- EPS (ttm)
- -0.68
- Shares out
- 53.33M
- Forward P/E
- -2.15
- YTD return
- -61.76%
- 1-year return
- -58.02%
- Volume
- 688.98K
- Avg volume
- 1.33M
- Open
- 0.7774
- Previous close
- 0.7593
- Day's range
- 0.751 – 0.7949
- 52-week range
- 0.631 – 3.06
- Beta
- 1.73
- Price target
- 10.25 (+1226.9%)
- Earnings date
- Aug 8, 2024
2Y -0.8107 (-50.99%)
Key statistics
- Enterprise value
- 93.76M
- PEG ratio
- 0.00
- Price / book
- 4.76
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -23.84M
- Total cash
- 83.25M
- Total debt
- 53.25M
- Return on equity
- -133.75%
- Short % of float
- 0.86%
- 50-day average
- 1.71
- 200-day average
- 1.58
Analyst view
- Target (low)
- 2.00
- Target (mean)
- 10.25
- Target (high)
- 25.00
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.15.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.16 | -0.14 | +0.02 | +12.50% |
| Aug 8, 2024 | Jun 1, 2024 | -0.19 | -0.14 | +0.05 | +26.32% |
| Aug 8, 2024 | Jun 1, 2024 | -0.19 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.26 | -0.21 | +0.05 | +19.23% |
| May 13, 2024 | Mar 1, 2024 | -0.26 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.30 | -0.32 | -0.02 | -6.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 22, 2024 | Rodman & Renshaw | init | — | Buy |
| Jul 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- milestonepharma.com
News
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026 
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation 
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences 
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial 
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR 
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Average Rating of “Moderate Buy” by Brokerages 
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target 
Milestone Pharmaceuticals Says China’s National Medical Products Administration Approves Etripamil Nasal Spray For Treatment Of Paroxysmal Supraventricular Tachycardia In Adults 
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
Your note
Sign in to keep a note on MIST — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.32% | 4,971,344 | 9.20M | Sep 29, 2024 |
| RTW Investments LP | 6.11% | 3,256,102 | 6.02M | Sep 29, 2024 |
| Millennium Management Llc | 5.21% | 2,778,525 | 5.14M | Sep 29, 2024 |
| Alta Fundamental Advisers LLC | 4.99% | 2,658,589 | 4.92M | Sep 29, 2024 |
| Citadel Advisors Llc | 3.87% | 2,061,522 | 3.81M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 3.75% | 2,000,000 | 3.70M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 0.04% | 19,311 | 35.73K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 17,576 | 32.52K | Oct 30, 2024 |
| JNL Series Trust-JNL/DFA U.S. Small Cap Fund | 0.00% | 1,661 | 3.07K | Sep 29, 2024 |